Hua Medicine (Shanghai) Ltd ("Hua" or the "Company", together with its subsidiaries and companies consolidated for accounting purposes, the "Group") is a China-based drug development company currently focused on developing a global first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 Diabetes (T2D). The shares in the Company are listed on the Main Board of the Stock Exchange of Hong Kong. The directors of Hua recognise the need to conduct the business of the Group with integrity and in accordance with suitable governance practices. The requisite improvements to the Group’s corporate governance procedures and policies have either been implemented or are in the process of being made.
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号